A COST UTILITY ANALYSIS OF MINOCYCLINE VERSUS ISOTRETINOIN IN STUBBORN ACNE
Author(s)
ABSTRACT WITHDRAWN
OBJECTIVES : In this study we evaluated cost-utility of Minocycline in comparison with Isotretinoin for treatment of patients with stubborn acne. METHODS : A decision-tree model from payer’s perspective was developed. Target population were Adults with moderate to severe acne and costs were expressed in 2019 U.S. dollars (1 USD= 42000 Rial). Success in treatment is defined as lowering in grad of acne underneath 1 and failure is determined due to no response, adverse effect and withdrawal. Direct medical costs per patient obtained from a national tariff book. Results were presented as costs per QALY. Since time horizon was 9 months, discounting wasn’t applied. One-way sensitivity analysis were conducted. Univariate deterministic and Probabilistic analysis were also conducted by means of 1000 Monte Carlo simulations. RESULTS : Model results indicated that use of minocycline is cost-saving. The incremental cost-effectiveness ratio (ICER) for this analysis was -38166.6 $ per QALY so it is considered dominant and cost-saving. Although Minocycline is less effective and more expensive than isotretinoin, higher chance of withdrawal and adverse events, longer treatment period and extra cost of Para clinic examinations and cosmetic products for isotretinoin leads to higher QALY and lower cost for Minocycline. CONCLUSIONS : Minocycline is cost-saving in comparison with isotretinoin for stubborn acne. According to the nature of economic evaluation which is strongly related to type of study and economic and clinical features, each country should run such studies of their own. Moreover, further research is needed to reduce uncertainty in the analysis and confirm data.
Conference/Value in Health Info
2019-11, ISPOR Europe 2019, Copenhagen, Denmark
Code
PIN17
Topic
Economic Evaluation
Disease
Infectious Disease (non-vaccine)